

Criteria Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Deutetrabenazine (Austedo®)

Notes:

- Quantity limits: Yes

Non-formulary **deutetrabenazine (Austedo®)** will be covered on the prescription drug benefit when the following criteria are met:

Tardive Dyskinesia:

Initiation (new start) criteria: Non-formulary **deutetrabenazine (Austedo)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescriber is a neurology or mental health clinician
- Patient has a diagnosis of tardive dyskinesia with symptoms present for at least 3 months
- Patient has history of antipsychotic medication, antidepressant medication, or metoclopramide use
- Abnormal movements are rated as moderate or severe indicated by either:
 - Abnormal Involuntary Movement Scale [AIMS] score ≥ 10 **OR**
 - Severity noted to be “moderate” or “severe” by prescriber **OR**
 - AIMS item 8 score of 3 or 4
- Deutetrabenazine is NOT being used concurrently with another vesicular monoamine transporter 2 (VMAT2) inhibitor, a monoamine oxidase inhibitor (MAOI), or reserpine.

Continued use criteria (12 months after initiation): Non-formulary **deutetrabenazine (Austedo)** will continue to be covered on the prescription drug benefit when the following criteria are met:

- Clinically significant improvement in abnormal movements verified by AIMS score or clinician observation

Criteria Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Deutetrabenazine (Austedo®)

Chorea associated with Huntington's disease:

Initiation (new start) criteria: Non-formulary **deutetrabenazine (Austedo)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is a neurology or mental health clinician
- Patient has documented choreiform movements secondary to Huntington's disease that cause impairment to daily activities
- Patient has documented contraindication, intolerance or treatment failure to tetrabenazine
- Deutetrabenazine is NOT being used concurrently with another vesicular monoamine transporter 2 (VMAT2) inhibitor, a monoamine oxidase inhibitor (MAOI), or reserpine